CNTB reports positive preliminary topline data
CNTB said its global Phase 2 study of rademikibart produced positive preliminary topline data.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod programNext study will test whether the formulation delivers measurable amounts of Entolimod into the bloodstreamSAN ANTONIO, TX / / September 30, 2026 / Valion Bio, Inc. NASDA…
Valion Bio and Shear Kershman Labs formulate oral mucosal Entolimod
Valion Bio reports that it and Shear Kershman Laboratories successfully formulated oral mucosal Entolimod. The company says it sees potential for multi-fold expansion of its long-term opportunity.